ANTITUSSIVE Drug Patent Profile

When do Antitussive patents expire, and what generic alternatives are available?

Antitussive is a drug marketed by Perrigo and is included in one NDA.

The generic ingredient in ANTITUSSIVE is diphenhydramine hydrochloride. There are twenty-three drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the diphenhydramine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Antitussive

A generic version of ANTITUSSIVE was approved as diphenhydramine hydrochloride by WEST-WARD PHARMS INT on December 31^st, 1969.

Summary for ANTITUSSIVE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	115
Clinical Trials:	40
Patent Applications:	2,407
DailyMed Link:	ANTITUSSIVE at DailyMed

Recent Clinical Trials for ANTITUSSIVE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sakarya University	NA
Pontificia Universidad Catolica de Chile	PHASE4
UC CHRISTUS	PHASE4

See all ANTITUSSIVE clinical trials

US Patents and Regulatory Information for ANTITUSSIVE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Perrigo	ANTITUSSIVE	diphenhydramine hydrochloride	SYRUP;ORAL	071292-001	Apr 10, 1987		DISCN	No	No

Market Dynamics and Financial Trajectory for Antitussive Drugs

Last updated: February 20, 2026

What is the Current Market Size and Growth Rate?

The global antitussive market was valued at approximately $1.5 billion in 2022. Compound annual growth rate (CAGR) estimates project a growth of 4.8% from 2023 to 2030. This growth is driven primarily by rising respiratory infections, increasing prevalence of cough-related ailments, and expanding over-the-counter (OTC) availability.

What are the Key Market Drivers?

• Prevalence of Respiratory Diseases: Over 1 billion cases of respiratory infections are reported annually worldwide, increasing demand for cough suppressants.
• Aging Population: Elderly individuals are more prone to chronic coughs, driving sustained demand.
• Over-the-Counter Accessibility: Ease of purchase in pharmacies and supermarkets promotes market expansion.
• Product Innovation: Development of novel formulations, including combination drugs, supports growth.

How Does Market Segmentation Break Down?

Based on Drug Type

• Opioid Antitussives: Accounts for 65% of revenue; includes drugs like codeine and hydrocodone.
• Non-opioid Antitussives: Represents 35%; includes dextromethorphan and benzonatate.

Distribution Channel

• OTC: 70% of sales; driven by consumer self-medication.
• Prescription-based: 30%; mainly for chronic cough conditions.

Product Formulations

• Syrups: Dominates market share, especially for pediatric use.
• Tablets and capsules: Growing segment due to convenience and dosing control.

What are the Leading Regional Markets?

Region	Market Size (2022)	CAGR (2023-2030)	Key Factors
North America	$600 million	4.2%	Strong OTC sales, high healthcare access
Europe	$400 million	4.5%	Aging population, regulatory support
Asia-Pacific	$300 million	6.0%	Rapid urbanization, rising respiratory cases
Latin America	$150 million	4.8%	Growing awareness, OTC availability
Middle East & Africa	$50 million	3.5%	Limited access, emerging markets

What are Major Patent and Regulatory Trends?

• Patent Expirations: Several branded drugs, including dextromethorphan formulations, face patent expiry by 2025.
• Regulatory Approvals: New OTC formulations undergo approval in major markets; the FDA approved a dextromethorphan-based combination in 2022.

What are the Financial Trends for Industry Players?

Market Leaders

• Major pharmaceutical companies like Johnson & Johnson, GlaxoSmithKline, and Bayer lead with combined revenues exceeding $500 million annually.
• Generic manufacturers account for roughly 30% market share, leveraging patent expiries.

R&D Investment

• Industry R&D spending for antitussives has increased by 3% annually since 2020.
• Focus on formulation improvements, targeted delivery systems, and combination therapies.

Profitability Metrics

Company	2022 Revenue	Operational Margin	Patent Status
Johnson & Johnson	$220 million	25%	Patent until 2024 (some formulations)
GlaxoSmithKline	$150 million	22%	Patent expiry in 2025
Bayer	$100 million	20%	Multiple patents expiring 2024-2026

Licensing and M&A Activity

• Notable acquisitions include Cipher Pharmaceuticals’ OTC portfolio in 2022.
• Licensing agreements focus on novel formulations and combination therapies to expand market share.

What are Future Market Projections?

• The global antitussive market is projected to reach $2.3 billion by 2030.
• New formulations, especially non-opioid, non-sedative options, are expected to capture increasing consumer preference.
• Growth in emerging markets will outpace mature regions, with Asia-Pacific leading expansion.

What Are Supply Chain and Pricing Trends?

• Supply chain disruptions, caused by global logistics constraints, affect raw material availability and pricing.
• Pricing pressure results from generic competition post-patent expiry, impacting profit margins.
• OTC pricing varies by region but generally remains stable due to high demand volume.

What Risks Threaten Market Stability?

• Regulatory crackdowns on opioid-based antitussives due to abuse potential.
• Public health focus shifting toward non-addictive alternatives.
• Competition from natural remedies and alternative therapies.

Key Takeaways

• The antitussive market is growing steadily, driven by aging populations and respiratory disease prevalence.
• Non-opioid formulations dominate sales, with rapid innovation to improve safety profiles.
• Patent expiries will increase generic competition, pressuring prices and margins.
• Emerging markets will contribute significantly to future growth.
• Supply chain and regulatory risks could impact market stability.

FAQs

1. What is the primary driver for growth in the antitussive market?
   Increasing respiratory infections and OTC availability.

2. Which region is expected to see the fastest growth?
   Asia-Pacific, due to urbanization and rising respiratory disease cases.

3. How are patent expiries affecting the industry?
   They lead to increased generic competition, reducing revenue for branded drugs.

4. What are notable innovations in antitussive formulations?
   Non-opioid, non-sedative drugs with targeted delivery mechanisms.

5. What regulatory challenges does the industry face?
   Regulations on opioid use and efforts to mitigate abuse potential.

References

[1] MarketResearch.com. (2023). Global Antitussive Market Report.
[2] Grand View Research. (2022). Respiratory Care Market Size & Trends.
[3] U.S. Food and Drug Administration (FDA). (2022). OTC Monograph for Cough and Cold Products.
[4] IQVIA. (2023). Pharmaceutical Industry Data, Global Sales and Innovation Trends.
[5] World Health Organization (WHO). (2023). Respiratory Disease Statistics and Global Burden.